Holen Sie sich die Stockscreener-App
1.65
4.43%
0.07
Okyo Pharma Limited Aktie (OKYO) Neueste Nachrichten
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 25.0% in March - MarketBeat
Aug Action: How does OKYO Pharma Limited compare to its peers - baoquankhu1.vn
Aug Sentiment: Is OKYO Pharma Limited a turnaround storyMarket Risk Report & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Gap Down: Can OKYO Pharma Limited beat the S P 5002026 Chart Watch & Safe Entry Point Alerts - baoquankhu1.vn
9 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting - Sahm
Small cap wrap: Replenish Nutrients, OKYO Pharma, Bit Digital, Record Resources… - Proactive financial news
OKYO Pharma to hold advisory board meeting at ASCRS conference By Investing.com - Investing.com South Africa
OKYO Pharma to hold advisory board meeting at ASCRS annual event - Investing.com India
OKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026 - Yahoo Finance
OKYO Pharma to Showcase Urcosimod Data and Convene Key Advisory Board at 2026 ASCRS Meeting - TipRanks
OKYO Pharma to hold advisory board meeting at ASCRS annual event By Investing.com - Investing.com South Africa
OKYO Pharma to hold advisory board meeting at ASCRS conference - Investing.com
OKYO Pharma (OKYO) showcases urcosimod Phase 2 data and plans 150-patient trial - Stock Titan
OKYO Pharma Announces Scientific Advisory Board Meeting and - GlobeNewswire
Income Plays: Is OKYO Pharma Limited stock trending bullishPortfolio Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
OKYO SEC FilingsOKYO PHARMA LTD 10-K, 10-Q, 8-K Forms - Stock Titan
Published on: 2026-03-31 02:21:38 - baoquankhu1.vn
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update - MarketBeat
How does OKYO Pharma Limited compare to its peersGlobal Markets & Accurate Buy Signal Notifications - baoquankhu1.vn
OKYO Earnings History & Surprises | EPS & Revenue Results | OKYO PHARMA LTD (NASDAQ:OKYO) - ChartMill
OKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial - The Globe and Mail
OKYO Pharma director acquires additional shares on NASDAQ By Investing.com - Investing.com Australia
OKYO Pharma executive chairman linked entity acquires additional shares on NASDAQ - Investing.com
OKYO Pharma Announces Chairman and Founder Acquires Shares - The Manila Times
OKYO Pharma director acquires additional shares on NASDAQ - Investing.com UK
OKYO Pharma executive chairman increases stake with share purchase - Proactive Investors
OKYO Pharma (NASDAQ: OKYO) chair adds shares as NCP drug advances - Stock Titan
OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3 - TipRanks
OKYO Pharma Announces Director Acquires Shares - The Manila Times
OKYO Pharma (NASDAQ: OKYO) director boosts stake with 5,000-share purchase - Stock Titan
OKYO Pharma director acquires 30,980 shares, increases total holding By Investing.com - in.investing.com
OKYO Pharma announces director stock purchase - proactiveinvestors.com
OKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress - TipRanks
OKYO Pharma director acquires 30,980 shares, increases total holding - Investing.com
OKYO Pharma Limited Reports Share Acquisition by Chief Development Officer and Advances in Neuropathic Corneal Pain Therapy Development - Quiver Quantitative
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares - The Manila Times
OKYO Pharma (NASDAQ: OKYO) CDO buys 30,980 shares at $1.59 - Stock Titan
OKYO Pharma reports quality of life improvements in pain trial By Investing.com - Investing.com India
OKYO Pharma (OKYO) Chief Development Officer reports stock and option holdings - Stock Titan
OKYO Pharma (OKYO) director Cerrone reports 10.5M common-share stake on Form 3 - Stock Titan
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial - Proactive Investors
Urcosimod Phase 2 NCP data show QoL gains, OKYO Pharma (OKYO) plans Phase 2b/3 - Stock Titan
OKYO Pharma reports quality of life improvements in pain trial - Investing.com
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain - The Manila Times
OKYO Pharma LTD - Via Ritzau
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February - MarketBeat
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):